Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
The leading Chinese CXO posted record revenue and strong profits last year, but its growth started to slow in the fourth quarter Key Takeaways: Wuxi AppTec’s chemical business doubled last…
Recent Articles
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
2359.HK
603259.SHG
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- As Covid drug cash dwindles, Vigonvita targets new remedies
